Despite recent reports, Lloyd’s hasn’t made any decision as to whether it will exit the captive market. The issue is under study as part of an overall review of Lloyd’s operations, due to be presented in October.
Lloyd’s spokesman Adrian Beeby indicated that the mistaken impression came from an interview with Lloyd’s Roger Sellek at a conference in the U.S. “Roger meant to indicate that the whole thing was more or less on hold, pending a complete review,” said Beeby. “For the present we’re not doing any new captive business, but we’re still a captive domicile.”
He indicated that Lloyd’s had only one captive insurer, which had been established by the pharmaceutical company Smith, Kline, Beecham. ” When they merged with Glaxo Wellcome, they essentially ceased writing new business, as Glaxo has other insurance arrangements.”
Topics Excess Surplus Lloyd's
Was this article valuable?
Here are more articles you may enjoy.
Howden-Driven Talent War Has Cost Brown & Brown $23M in Revenue, CEO Says 
Florida Board Drafting Rules That Could Stem Bogus Engineering Reports in Claims 
Navigators Can’t Parse ‘Additional Insured’ Policy Wording in Georgia Explosion Case 
LA Fire Survivors Got a Rude Surprise That Could Hit More Americans 
